Skip to main content

Table 1 Comparison of the canonical pathways

From: Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer

Comparison A: Wt MCF7+E2 versus week 1   Comparison A: Wt MCF7+E2 versus week 1  
Interferon signalling 2.79 E-07 Purine metabolism 1.13 E-12
Molecular mechanisms of cancer 1.17 E-05 Pyrimidine metabolism 2.11 E-10
JAK/STAT signalling 2.72 E-05 Protein ubiquitination pathway 6.48 E-08
Germ cell-steroli cell junction signalling 2.76 E-05 Role of BRCA1 in DNA damage response 6.92 E-08
Inositol phosphate metabolism 1.15 E-04 Mitotic roles of polo-like kinase 5.72 E-07
IL-3 signalling 1.63 E-04 Role of CHK proteins in cell cycle checkpoint control 1.41 E-06
PDGF signalling 1.94 E-04 ATM signalling 3.06 E-06
Neuregulin signalling 2.15 E-04 Cell cycle:G2/M DNA damage checkpoint regulation 1.23 E-05
Erythropoietin signalling 2.31 E-04 Cleavage and polyadenylation of pre-mRNA 1.24 E-04
PI3K/AKT signalling 2.95 E-05 Alanine and aspartate metabolism 5.15 E-04
Comparison B: Week 1 versus week 9   Comparison B: Week 1 versus week 9  
Mitotic roles of polo-like kinase 4.71E-08 Antigen presentation pathway 8.88E-20
Role of CHK proteins in cell cycle checkpoint control 2.08E-07 Interferon signalling 1.44E-17
ATM signalling 3.27E-07 Activation of IRF by cytosolic pattern recognition receptors 2.48E-10
Role of BRCA1 in DNA damage and response 8.75E-06 Role of pattern recognition receptors in recognition of bacteria and viruses 2.37E-07
Hereditary breast cancer signalling 2.08E-05 Dendritic cell maturation 3.54E-06
Pyrimidine metabolism 3.34E-05 Allograft rejection signalling 7.64E-06
Cell cycle: G2/M DNA damage checkpoint regulation 1.57E-04 Autoimmune thyroid disease signalling 1.04E-05
   Graft-versus-host disease signalling 1.21E-05
   Role of RIG1-like receptors in antiviral innate immunity 1.39E-05
   Cross talk between dendritic cells and natural killer cells 2.02E-05
Comparison C: Wt MCF7+E2 versus week 9   Comparison C: Wt MCF7+E2 versus week 9  
PDGF signalling 1.15E-07 Protein ubiquitination pathway 1.63 E-07
Molecular mechanisms of cancer 1.53E-07 Purine metabolism 6.49 E-07
Actin cytoskeleton signalling 4.92E-07 Pyrimidine metabolism 7.92 E-06
Integrin signalling 6.93E-07 Mitochondrial dysfunction 1.25 E-04
PI3K/AKT signalling 1.06E-06 Oxidative phosphorylation 2.47 E-04
EGF signalling 5.88E-06 Citrate cycle 4.79 E-04
FAK signalling 8.45E-06 Role of BRCA1 in DNA damage response 7.53 E-04
HGF signalling 1.23E-05 Lysine degradation 7.84 E-04
14-3-3 mediated signalling 1.30E-05   
Neuregulin signalling 1.53E-05   
Ephrin Receptor Signaling 1.66E-05   
IGF-1 Signaling 1.85E-05   
ILK Signaling 2.27E-05   
Axonal Guidance Signaling 3.12E-05   
JAK/Stat Signaling 6.14E-05   
Insulin Receptor Signaling 6.17E-05   
  1. ATM, ataxia teleangiectasia mutated; BRCA1, breast cancer type 1 susceptibility protein; CHK, csk-homologous kinase; E2, estradiol; EGF, epidermal growth factor; FAK, focal adhesion kinase; HGF, hepatocyte growth factor; IGF-1, insulin-like growth factor 1; IL-3, interleukin 3; ILK, integrin-linked kinase; IRF, interferon regulatory factor; JAK, Janus kinase; PDGF, platelet-derived growth factor; PI3K, phosphatidylinositol 3-kinase; RIG1, retinoid-inducible gene 1; STAT, Signal Transducer and Activator of Transcription;